CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P. Morgan Healthcare Conference. The conference will take place January 12-15, 2026, in San Francisco, California. Details regarding Lifecore’s participation are as follows: 44th Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, includi ...

Core Insights - Lifecore Biomedical reported $31.1 million in revenue for the three months ended September 30, 2025, marking a 26% increase from the same period in 2024 [11][4] - The company has signed multiple new programs with customers, indicating growth in its project pipeline [8][3] - Lifecore is focused on improving efficiency and productivity across its operations, achieving over a 20% increase in workforce productivity in manufacturing over the past year [7][4] Financial Performance - Revenue increased by $6.4 million compared to the prior year, driven by a $4.8 million rise in hyaluronic acid (HA) manufacturing revenues and a $1.6 million increase in CDMO revenues [11][12] - Gross profit for the period was $7.8 million, up from $5.4 million in the prior year, attributed to increased sales volume and manufacturing absorption [12][11] - Selling, general, and administrative expenses decreased significantly to $8.9 million from $14.8 million, reflecting cost management efforts [13][11] Strategic Initiatives - Lifecore's growth strategy includes maximizing existing customer business, advancing late-stage development programs, and acquiring new impactful business [3][4] - The company is preparing for a significant increase in customer demand expected in 2027 by qualifying new HA specifications for the Asian market [5][4] - Lifecore plans to implement a new enterprise resource planning (ERP) system in Q1 2026 to enhance inventory control and financial management [9][4] Future Guidance - For the transition period from May 26 to December 31, 2025, Lifecore expects revenue between $74 million and $76 million, with a net loss projected between $18.4 million and $16.4 million [19][10] - Adjusted EBITDA for the transition period is anticipated to be in the range of $12 million to $14 million, reflecting the company's ongoing efforts to grow and diversify its revenue streams [19][10]

Core Insights - Samsung Biologics has introduced ExellenS, an optimized manufacturing framework aimed at enhancing biomanufacturing efficiency and consistency across its facilities [1][2][3] Group 1: ExellenS Framework - ExellenS standardizes equipment, processes, and specifications to ensure uniformity and high-quality outcomes across all manufacturing sites [2][3] - The framework is built on four pillars: client satisfaction, operations, quality, and people expertise, which help maintain competitiveness as a global CDMO [3][4] - ExellenS integrates Functional Design Specifications (FDS) to replicate bioreactor configurations and automation systems, allowing for tailored improvements while minimizing risks [4][6] Group 2: Speed to Market - The ExellenS framework accelerates global regulatory readiness and tech transfers, enabling clients to launch products on time and scale operations seamlessly [5][9] - Standardized systems and streamlined operations reduce risks and changeover times, providing clients with the flexibility needed in a complex market [5][9] Group 3: Supply Chain Resilience - ExellenS enhances supply chain continuity through dual-sourcing and multi-plant production, integrating digital platforms for improved agility and resilience [6][11] - The framework minimizes variability between plants, allowing for rapid technology transfers and ensuring compliance and audit readiness [6][11] Group 4: Future Capacity and Commitment - Samsung Biologics currently has a manufacturing capacity of 784,000 liters across five plants and plans to expand this capacity through 2032 [7][10] - The company is dedicated to delivering high-quality products on time and making sustainable business decisions to benefit global health [12]

Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid and serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Upcoming Financial Results - Lifecore will report its financial results for the fourth quarter and fiscal year 2025 on August 7, 2025, after market close [1] - A webcast hosted by Lifecore's senior management team will take place at 4:30 p.m. Eastern Time on the same day to discuss the results [1][2] Webcast Access - Investors can listen to the live webcast or access the archived version on Lifecore's Investor Events & Presentations page [2] - The archived version will be available for 30 days following the live event [2] Contact Information - Lifecore's investor relations contact is Stephanie Diaz from Vida Strategic Partners, reachable at 415-675-7401 [4] - Media inquiries can be directed to Tim Brons at 415-675-7402 [4] - Ryan D. Lake serves as the CFO of Lifecore Biomedical and can be contacted at 952-368-6244 [4]

Core Viewpoint - BGM Group Ltd is undergoing a significant leadership transition aimed at enhancing its technological transformation and sustainable growth, with a focus on innovation and strategic upgrades in response to market opportunities and challenges [1][5]. Leadership Changes - Mr. Zhanchang Xin has resigned as Chairman, effective March 1, 2025, and will be succeeded by Mr. Chen Xin, the current CEO [2][3]. - Mr. Chen Xin has extensive experience in market consolidation and corporate management, having led the acquisition of Duxiaobao Intelligent Technology and previously worked in autonomous driving algorithm development [3][4]. - Mr. Lin Zhang has been appointed as an independent director and will chair the compensation committee, bringing rich experience in AI model architecture and deep learning projects [4][5]. Strategic Focus - The company is strategically focused on technology fields including AI applications, intelligent robots, algorithmic computing power, cloud computing, and biopharmaceuticals [6]. - BGM Group utilizes big data mining and AI Agent technology to provide comprehensive AI solutions and intelligent robot services, particularly in the insurance sector [7]. - In biopharmaceuticals, the company produces key products like oxytetracycline API and crude heparin sodium, integrating AI-assisted decision-making to optimize production and supply chain processes [8].